MEDICINE ECONOMIC REPORTER：Two Powerhouses Lead the Surgical Powertrain Market

According to MDCLOUD’s public bidding data, the surgical power system market in China showed a more concentrated trend in the first quarter of 2024. The top four brands in terms of sales accounted for nearly 70% of the total, an increase of about 13 percentage points compared to 57% in the same period last year. Among them, Xishan and Medtronic were particularly prominent, with a combined market share of over 63%.

From the perspective of market structure, the growth of domestic brand Xishan in market share is particularly significant, ranking first among domestic brands. At the same time, brands such as Medtronic and MEDAIDEZR Power have also achieved steady growth in market share. Among multiple provinces, Xishan ranked first in sales in 11 provinces including Sichuan, Fujian, and Hubei due to its excellent performance and service. Medtronic held a leading market share in five provinces including Zhejiang, Guangxi, and Chongqing.

From a hospital level perspective, tertiary hospitals remained the main purchasers of surgical power systems in the market, accounting for 67.02%, a slight increase compared to the same period last year. However, the market share of secondary hospitals  declined, indicating a trend of concentration in the surgical power system market towards higher-level medical institutions. In both tertiary and secondary hospitals, the two major brands, Xishan and Medtronic, held a dominant position with a combined market share of over 60%.

In both tertiary and secondary hospitals, the two major brands, Xishan and Medtronic, held a dominant position with a combined market share of over 60%. In the county-level hospital market, the two major brands, Xishan and Medtronic, also performed well, ranking among the top two in terms of procurement market share.

In the surgical power system market, domestic brands always faced competitive pressure from international brands. However, in recent years, domestic brands have achieved significant results through technological advancements and improvements in craftsmanship. In the first quarter of 2024, the market share of domestic brands increased by 10.30% compared to the same period last year, reaching 55.82%. Domestic brands are gradually narrowing the gap with international brands.

According to MDCLOUD statistics, the number of orthopedic and neurosurgical surgeries in China increased by 10.1% and 7.9% respectively in 2023, and it is expected to maintain a growth rate of over 7% in the next three years.

China is encouraging China end uses for more domestic products in latest years. Thus, more and more overseas manufacturers are planning localization in China. BradyKnows localization team has extensive experiences in facility establishment, audit, supplier evaluation, manufacturing, registration, and marketing in China. Pls feel free to let us know any questions on China entry via info@bradyknowsmedical.com

Source：MEDICINE ECONOMIC REPORTER

Translated & edited： Bradyknow